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Designer T cells expressing transgenic T cell receptors (TCR) with anti-tumor specificity offer new treatment options for
cancer patients. We developed a three phase procedure to identify T cells of high avidity based on the fact that T cells
recognizing peptides presented by allogeneic MHC efficiently kill tumor cells. Autologous dendritic cells (DC) are co-
transfected with ivt-RNA encoding an allogeneic MHC molecule and a selected antigen to allow them to express
allogeneic MHC-peptide complexes that activate allo-restricted peptide-specific T cells. This approach provides great
flexibility for obtaining high-avidity T cells as potential sources of TCR for adoptive T cell therapy.
Introduction
The rapidly expanding field of adoptive T cell transfer for
immunotherapy of cancer has revealed the important need to have
sources of T cells that can effectively recognize and eliminate
different types of malignant cells. The power of adoptive cell
therapy to induce complete tumor remission lasting over many
years has been clearly demonstrated in patients undergoing
allogeneic hematopoietic stem cell transplantation (HSCT). In
this setting, genetic differences between the donor and the patient
enable strong T cell responses directed against minor histocom-
patibility determinants to eradicate malignant leukemia clones of
the patient.
1-3 Complete remissions often occur only after several
months up to one year following donor leukocyte infusion (DLI),
due to the need for specific T cells to be activated and expanded to
adequate numbers in vivo. This time lag places limits on the
efficacy of DLI in the treatment of acute leukemia after HSCT,
since the growth of residual malignant cells often outpaces the
expansion capacity of specific immune cells.
4,5 Furthermore, this
therapy option is not available for many patients who cannot
undergo HSCT.
For immunotherapy of solid tumors, the adoptive transfer of
tumor-infiltrating lymphocytes (TIL) has provided substantial
clinical benefit for numerous patients, particularly those with
melanoma.
6-8 However the failure to obtain adequate numbers of
TIL with good function hinders the treatment of many patients.
Many TIL recognize self-MHC molecules that present peptides
derived from self-proteins.
6 These T cells are usually of low avidity
because negative selection of high-avidity T cells recognizing self-
proteins occurs in the thymus to prevent autoimmunity
7 however
high-avidity T cells are needed to effectively eradicate tumor cells.
Furthermore, the isolation and large-scale expansion of tumor-
associated antigen (TAA)-specific T cells for each patient is
expensive and time consuming. Thus, a new therapeutic strategy
aims to rapidly imbue activated patient T cells with tumor
specificity and high functional avidity by using transgenic
expression of selected TCR sequences (TCR gene therapy).
Clinical studies have utilized several patient-derived transgenic
TCR (tg-TCR) in phase I trials of advanced melanoma.
8
When compared with adoptive transfer of heterogenous TIL,
these initial trials suggested that clinical efficacy may require use
of mini-repertoires of lymphocytes expressing different tg-TCR.
Unfortunately, tg-TCR therapy was often accompanied by
substantial toxicity due to cross-recognition of normal tissues,
particularly when a TCR of higher avidity was used.
8 Animal
studies have also revealed that adoptive transfer of high-avidity tg-
TCR specific for p53 leads to recognition of stem cells, causing
hematological cell loss and death of recipient animals.
9 Therefore,
it is of critical importance to select tg-TCR for clinical application
that will provide the best gain in clinical efficacy with the lowest
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toxicity for self-tissues. This requires careful selection of the TAA
that should serve as targets for tumor recognition, as well as
careful selection of the corresponding therapeutic tg-TCR. While
a number of TAA candidates have been identified over the past
decades that may prove to be suitable target molecules, including
tissue-restricted proteins and cancer-testis antigens,
10 there is still a
critical need to have access to more TCR that can be utilized for
TCR gene therapy. In the end, rigorous selection of both the
target TAA and the corresponding tg-TCR sequence will be
needed to achieve optimal discrimination between tumor cells
and normal tissues. However, after these parameters have been
established, a tg-TCR can be widely used for large numbers of
patients whose tumors express the corresponding tg-TCR ligand.
The problem of acquiring only low-avidity T cells as sources of
tg-TCR, due to negative selection, can be bypassed because this
selection process is limited to self-MHC molecules that are
expressed in the thymus.
11 Therefore, it is possible to isolate T
cells of high avidity that recognize peptides derived from any TAA
if they are presented by allogeneic MHC molecules. Previous
work showed that transgenic lymphocytes that express allo-
restricted peptide-specific tg-TCR can effectively eliminate tumor
cells in pre-clinical models.
12 The most common approach to
obtain allo-restricted T cells uses peptide-pulsed T2 cells as
antigen-presenting cells (APC). However, many T cell clones
generated in this manner fail to kill tumor cells. As an alternative,
activated B cells have been used following coating with allogeneic
peptide-MHC (pMHC) monomers.
13 This method takes advant-
age of the professional APC capacity of activated B cells, but it
requires the development of many different pMHC-monomers if
it is to be applied for numerous TAA. Allo-restricted peptide-
specific T cells can also be obtained using peptide-loaded APC or
tumor cells to stimulate T cells derived from HLA partial-
mismatched individuals if suitable donor pairs can be identified.
Here a major drawback is the rarity of individuals that differ by
only one HLA allotype of choice, restricting the ability to use
some HLA allotypes for peptide presentation. Therefore all of
these approaches have major limitations for generating allo-
restricted TAA-specific T cells with high functional avidity.
To overcome these obstacles we developed a procedure to isolate
allo-restricted peptide-specific T cells as sources of high avidity tg-
TCR which uses in vitro transcribed RNA (ivt-RNA)-transfected
dendritic cells (DC) as APC. This method utilizes the important
capacity ofmature DC(mDC) toprime naïve lymphocytes.
14 Inthe
experimental procedure, T cells are co-cultured with autologous
mDC that have been loaded with ivt-RNA which encodes a selected
TAA, combined with ivt-RNA encoding a selected HLA allele that
isnot carried bythe donor.Both proteinsare expressed bythemDC
and thereby new allo-pMHC ligands are presented at thecellsurface
where they function to activate allo-restricted peptide-specific
responses in autologous T cells.
Results
T cells are generated using a three phase experimental procedure.
The generation of allo-restricted peptide-specific T cells using mDC
pulsed with ivt-RNA encompasses an experimental procedure that
includes three distinct phases (Fig.1). The first phase involves the
generation of mDC from peripheral blood monocytes. This phase is
spread over a time period of eight days, beginning on day -8 with
respect to initiation of the primary (1°) mDC-T cell co-cultures that
areestablishedonday0.Asimilarproceduremustalsobeperformed
to prepare fresh mDC for use in the secondary (2°) co-cultures of
mDC and 1° T cells. Therefore, a new set-up is performed in an
identical manner, whereby the monocytes are isolated from fresh
peripheral blood samples on day -1, in order to have mDC available
for harvest and use when the 2° co-cultures are established on day 7.
The second phase of the experimental procedure involves the
co-culture of CD8-enriched T cells with the ivt-RNA-pulsed
mDC. The 1° co-cultures are established on day 0 and use mDC
that are freshly loaded with ivt-RNA via electroporation. After ivt-
RNA-loading, the mDC are cultured for 10 h in DC medium
supplemented with 100 ng/ml GM-CSF and 20 ng/ml IL-4. After
10 h in DC medium, the mDC are harvested, counted and added
to the pre-seeded T cells. The co-culture is performed in T cell
medium. CD8
+ T cells are generated from freshly drawn
peripheral blood samples obtained on day 0. After Ficoll density
centrifugation the lymphocytes undergo CD8-enrichment
through depletion of contaminating lymphocyte populations with
the use of a commercial kit. After washing and counting, mDC
and CD8
+ T cells are co-cultured at a ratio of 1:10. We aim to
stimulate 2x10
7 T cells in the 1° co-cultures. This number can
vary dependent upon the numbers of viable mDC that are
available after loading of ivt-RNA. The 1° co-cultures are
continued for seven days, at which time the T cells are harvested,
counted and replated with freshly prepared ivt-RNA-pulsed
mDC, established from freshly isolated monocytes on day -1.
The primed T cells are recovered on day 7 from the 1° co-cultures,
washed, counted and resuspended in fresh culture medium. A
ratio of 1:10 for mDC to T cells is also used in the 2° co-cultures.
The numbers of primed T cells that can be replated in 2° co-
cultures is dependent upon the numbers of viable mDC that are
available for restimulation.
The third phase of the experimental procedure involves an
enrichment step based on MHC-multimer sorting to obtain T
cells that express TCR which recognize a pMHC ligand that is
newly expressed on the mDC following transfection with both
ivt-RNA. The T cells recovered from the 2° co-cultures are
incubated with PE-labeled pMHC-multimer and APC-labeled
antibody specific for CD8. The double-positive cells are gated and
sorted using either MoFlo or FACS Aria instruments. The
multimer
+ T cells are then immediately cloned in limiting dilution
cultures. The remaining T cells are cultured in bulk to establish
corresponding T cell lines. Both the T cell clones and the T cell
lines are restimulated non-specifically every 14 d with anti-CD3
antibody and feeder cells.
Allogeneic MHC molecules are provided to mDC by ivt-RNA.
In order to stimulate allogeneic T cells, some of which are peptide-
specific, the mDC must express allogeneic MHC molecules at the
cell surface after transfer of ivt-RNA encoding an HLA allotype.
Since mDC display high levels of endogenous MHC class I, the
surfaceexpressionoftransgenicallogeneicMHCmustbemonitored
using HLA allotype-specific monoclonal antibodies to analyze cells
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by flow cytometry. For example, expression of transgenic HLA-A2
molecules can be studied on mDC prepared from HLA-A2
- donors
using a primary HLA-A2-specific BB7.2 monoclonal antibody,
followed by a secondary PE-conjugated antibody. As an example
HLA-A2 surface expression was already detected on the mDC
surface at 1.5 h following electroporation of 25 mg ivt-RNA
encoding the HLA-A*0201 allele (Fig.2A). In this case, HLA-A2
expression reached a peak at 10 h, measured as mean fluorescent
intensity (MFI), and then decreased over time. Nevertheless,
around 50% of the mDC were still positive for HLA-A2 at 120 h.
The greatest percentage of HLA-A2
+ mDC (63%) was also seen
at 10 h.
Various forms of ivt-RNA can be used to transfect mDC for
allogeneic MHC expression. We analyzed four sources of ivt-RNA
that contained a-globin or  -globin domains in the 3' region,
introduced to increase mRNA stability. The 3' untranslated region
of both the human a-globin and  -globin-gene was linked to
the HLA-A2 construct in different ways leading to a-globin
stabilized and  -globin stabilized HLA-A2 ivt-RNA. These four
globin-stabilized ivt-RNA were compared with a standard ivt-RNA
that was generated according to published procedures using
commercially-available kits and reagents.
15,16 This ivt-RNA carried
a poly-A tail but did not contain any extra globin domain. When
mDC were loaded with the different sources of RNA and analyzed
by flow cytometry, a similar kinetics of HLA-A2 surface expression
was observed, but use of ivt-RNA carrying a globin domain
to improve mRNA stability did not increase the levels of surface
HLA-A2. In fact, substantially higherlevels of HLA-A2 wereseen in
mDC expressingthestandardivt-RNA (Fig.2B).The differencesin
levels of HLA-A2 surface expression imbued by the various RNA
also impacted on the capacity of the mDC to stimulate cytokine
secretion by a T cell clone (JB-4) that recognizes HLA-A2 as an
alloantigen.
17 JB-4 cells released a far greater amount of IFNc after
stimulation with standard ivt-RNA (Fig.2C).
Co-expression of ivt-RNA encoding MHC and antigen creates
new peptide-MHC ligands. New pMHC ligands of defined specifi-
city can be created on mDC by introducing two different species of
ivt-RNA, one encoding anallogeneic HLA and the secondencoding
Figure1. Time schedule of a de novo stimulation protocol for naïve CD8-enriched T cells with ivt-RNA-pulsed DC. The generation of DC of HLA-A2
+ and
HLA-A2
- donors is started eight days before priming (day -8). Monocytes are isolated from PBMC by plastic adherence on day 0 and cultured for 6 d with
GM-CSF and IL-4 to produce immature DC (iDC) which are then incubated with a maturation cocktail. After 48 h, mature DC (mDC) are harvested and
used for the T cell priming (day 0). Mature DC of HLA-A2
+ donors are electroporated with TAA-ivt-RNA and mDC of HLA-A2
- donors are transfected with
ivt-RNA encoding the allo-MHC molecule HLA-A2, in combination with ivt-RNA encoding the TAA. RNA concentrations depend on the MHC molecules
and the TAA that are used. Ten hours after electroporation, priming (1°) is initiated by co-culture of autologous CD8-enriched T cells with ivt-RNA-loaded
mDC in a ratio of 10:1. The second stimulation (2°) is performed seven days later (day 7) using freshly prepared ivt-RNA-pulsed mDC. On day 14, the TAA-
specific HLA-A2-restricted T cell cultures are stained with multimer and sorted via fluorescence activated cell sorting. The sorted T cells are cloned in
limiting dilution cultures or expanded as bulk lines. Thereafter T cells are non-specifically stimulated every 14 d.
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a new antigen, for example a defined TAA. To demonstrate that
both proteins, encoded by the two co-transfected ivt-RNA species,
are expressed in the mDC after electroporation, we used ivt-RNA
encoding HLA-A2 combined with ivt-RNA encoding tyrosinase,
which is expressed in many melanomas, as a model TAA. As shown
above, HLA-A2 expression was easily monitored by surface staining
of mDC. Tyrosinase expression was monitored by intracellular
staining using tyrosinase-specific antibody since itis not expressed as
a membrane protein.
In this analysis, two concentrations (24 mg and 48 mg) of
ivt-RNA encoding HLA-A2 and tyrosinase were introduced
simultaneously by electroporation into mDC prepared from an
HLA-A2
- donor (Fig.3A). The intracellular expression of tyro-
sinase was analyzed after 3 h and surface expression of HLA-A2
Figure2. Kinetics of HLA-A2 expression
and stimulatory capacity of ivt-RNA-
transfected mDC from an HLA-A2
- donor.
(A) HLA-A2
- mDC are electroporated with
25 mg HLA-A2 ivt-RNA prepared by the
standard method. Surface staining of
HLA-A2 is performed at different time
points (1.5 h, 3 h, 6 h, 10 h, 24 h, 48 h and
120 h) after transfection and analyzed by
flow cytometry. Stained samples are
represented by filled gray curves and
corresponding controls by empty curves.
Percent positive cells, mean fluorescence
intensity (MFI) and x-fold expression are
shown in the upper right corner of each
histogram. The x-fold expression is cal-
culated by dividing the MFI of the
positive sample with the MFI of the
control. (B) For comparison, mDC of an
HLA-A2
- donor are transfected with 25 mg
of 5 different species of HLA-A2 ivt-RNA.
The quality of the standard poly-A tail
(pAAA)-stabilized HLA-A2 ivt-RNA is
compared with a-globin-stabilized (1, 2,
3) and b-globin-stabilized HLA-A2 ivt-
RNA. The expression at different time
points is depicted in a bar histogram as
MFI. (C) mDC transfected with the various
HLA-A2 ivt-RNA species are used 24 h
after electroporation for co-incubation
with the HLA-A2 allo-reactive CTL clone
JB4 to assess their stimulatory capacity.
IFNc is quantified in culture supernatants
by ELISA and presented as pg/ml. Mean
values and mean deviations are derived
from duplicate measurements.
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was assessed at 6 h, based on preliminary studies of each
individual protein (data not shown). The percentages of HLA-A2
+
mDC increased from around 30% using 24 mg ivt-RNA (Fig. 3A,
panels 1 and 2) to around 60% using 48 mg ivt-RNA (Fig. 3A,
panels 3 and 4). Only a small but non-significant increase in the
percentages of mDC expressing intracellular tyrosinase protein
was observed when the concentration of tyrosinase ivt-RNA was
doubled (Fig. 3A, panels 1 and 3 vs. 2 and 4). A paradoxical
decrease in HLA-A2 expression was seen when the concentration
of tyrosinase ivt-RNA was increased, leading to a decrease in MFI
from 101 when 24 mg of tyrosinase ivt-RNA (Fig. 3A, panel 3)
was used to a MFI of only 53 when 48 mg of tyrosinase ivt-RNA
was co-expressed in the mDC (Fig. 3A, panel 4). This suggested
that the total amount of ivt-RNA expressed in the mDC might be
Figure3. Co-expression of two different ivt-RNA species encoding HLA-A2 and tyrosinase. mDC are electroporated with four different ivt-RNA
combinations: (1) 24 mg HLA-A2 and 24 mg tyrosinase ivt-RNA, (2) 24 mg HLA-A2 and 48 mg tyrosinase ivt-RNA, (3) 48 mg HLA-A2 and 24 mg tyrosinase ivt-
RNA and (4) 48 mg HLA-A2 and 48 mg tyrosinase ivt-RNA are mixed and co-transfected into mDC of an HLA-A2
- donor. (A) Surface staining of HLA-A2 is
performed at 6 h and intracellular staining of tyrosinase at 3 h after transfection and analyzed by flow cytometry. HLA-A2 expression is represented by
filled curves, corresponding tyrosinase expression of the same sample is shown beneath by filled curves. Mock-control mDC are included in the
respective histograms by open curves. Percent positive cells, MFI and x-fold expression are shown in the upper right corner of each histogram.
(B) Stimulatory capacity of the mDC loaded with different concentrations of HLA-A2 and tyrosinase ivt-RNA is analyzed by induction of IFNc secretion of
specific T cell clones. Columns represent the amount of IFNc (pg/ml) secreted by a tyrosinase-independent HLA-A2 allo-reactive CTL (JB4) and an
HLA-A2-restricted tyrosinase peptide-specific CTL (Tyr-F8) after co-incubation with ivt-RNA-pulsed DC, 24 h after electroporation. IFNc is quantified in
culture supernatants by ELISA. Mean values and mean deviations are derived from duplicate measurements. IFNc secretion of T cells alone and in
co-culture with non-transfected mock mDC serve as negative controls. Maximal IFNc release of the CTL is observed in co-cultures with the tumor
cell line Mel-93.04A12 as the positive control.
www.landesbioscience.com OncoImmunology 133© 2012 Landes Bioscience.
Do not distribute.
inhibitory. This observation was similar to effects we observed
when multiple sources of ivt-RNA that encode different TAA
were introduced into mDC.
The response of a T cell clone (Tyr-F8) that is specific for a
new pMHC ligand comprised of tyrosinase peptide369–377 pre-
sented by HLA-A2 was assessed to determine whether peptides
were processed from the tyrosinase protein and presented on the
mDC surface in association with transgenic HLA-A2 molecules.
18
First, T cell recognition of HLA-A2 as an alloantigen expressed
by the mDC, irrespective of specific peptide, was seen with clone
JB-4. This clone responded with the highest level of IFNc
secretion after 24 h co-culture with mDC loaded with 48 mg of
HLA-A2 and 24 mg of tyrosinase ivt-RNA (Fig. 3A, panel 3),
which corresponded to the highest MFI of HLA-A2 on the mDC
(Fig.3B). As shown in Figure2, JB-4 cells also recognized trans-
genic HLA-A2 molecules on mDC in the absence of tyrosinase
protein, demonstrating their independence from tyrosinase
peptide. Clone Tyr-F8 responded to all four mDC populations,
with the greatest response seen when 48 mg of each ivt-RNA was
used (Fig. 3A, panel 4 and Fig.3B). Published results demon-
strated that activation of this clone was dependent upon the
co-expression of HLA-A2 and tyrosinase protein in the mDC.
When co-expression was analyzed using independent sources
of mDC, the lower concentrations of ivt-RNA depicted in
panels 1 and 2 (Fig.3A) were generally found to stimulate weaker
responses of Tyr-F8 cells than mDCs loaded with higher con-
centrations of ivt-RNA, as depicted in Figure 3A, panels 3 and 4.
This revealed that both the percentages of HLA-A2
+ mDC as
well as the level of HLA-A2 expression were important. The
small variations in tyrosinase protein expression seemed not to be
relevant (Table 1).
Co-expression of other ivt-RNA combinations allows HLA
and TAA expression on mDC. To establish that other combina-
tions of ivt-RNA also led to strong co-expression of MHC and
TAA in mDC, we analyzed melan-A and survivin as TAA,
together with HLA-A2. Again, transgenic expression of HLA-A2
was monitored by surface staining and TAA protein expression
was detected by intracellular staining. The amounts of ivt-RNA
introduced into the mDC were also varied. With both combina-
tions, it was also possible to detect high percentages of HLA-A2
+
mDC and TAA
+ mDC with substantial levels of protein expres-
sion (Fig.4). These results demonstrated that this approach
provides a robust method to efficiently generate mDC that co-
express new MHC and TAA. Furthermore, the same method
could be easily used to introduce ivt-RNA only encoding a TAA
into mDC that naturally expressed the desired HLA restriction
element due to presence of the endogenous class I allele, as shown
in Figure 4, panels 5 and 6 for both melan-A and survivin
(Fig.4).
Once again, some decrease in the MFI of HLA-A2 expression
was detected in the presence of melan-A or survivin ivt-RNA.
This was observed for melan-A (Fig.4, panel 2 vs. 1) when the
amount of melan-A ivt-RNA was doubled. Although not as
dramatic, a small change in MFI of melan-A was seen when 25 mg
of TAA ivt-RNA was used and the concentration of HLA-A2 ivt-
RNA was increased from 25 mgt o5 0mg( Fig.4, panel 1 vs. 3)
(Fig.4A). In mDC co-expressing HLA-A2 and survivin, the
decrease in HLA-A2 expression was greatest when 50 mgo f
survivin ivt-RNA was combined with 50 mg of HLA-A2 ivt-RNA
(Fig.4B, panel 4). A reciprocal impact on survivin expression
was not observed. Thus, expression of HLA-A2 seemed to be
more susceptible to interference, although impacts on TAA
expression may be more difficult to precisely quantify because of
the more complex method used to detect intracellular proteins by
antibody staining. The reasons for inhibition are not clear since
higher amounts of ivt-RNA were not necessarily detrimental; it
appears that the ratio of the two species of RNA may also play
some role. Nevertheless, all of the mDC populations still showed
high percentages of positive cells with substantial MFI of both
HLA and TAA protein expression, indicating the suitability of
using ivt-RNA to enable good co-expression of these protein
combinations in mDC.
Table1. Stimulatory capacityof mDCloadedwithdifferentamountsofivt-RNA
IFN-c release relative to tumor [%]
HLA-A2 tyrosinase Exp. 1 2 3 mean
Tyr-F8 24 mg2 4 mg 0.0 1.5 4.1 1.9
mDC* mock 24 mg4 8 mg 3.6 2.2 4.0 3.3
mDC 1 48 mg2 4 mg 14.0 3.6 9.9 9.2
mDC 2 48 mg4 8 mg 8.6 7.9 7.5 8.0
mDC 3 14.0 14.7 12.1 13.6
mDC 4 7.4 17.5 7.8 10.9
tumor cells 100.0 100.0 100.0 100.0
Figure4 (See opposite page). Co-expression of additional combinations of ivt-RNA encoding TAA and MHC. (A) mDC of an HLA-A2
- donor are
electroporated with four different RNA combinations: (1) 25 mg HLA-A2 and 25 mg melan-A ivt-RNA, (2) 25 mg HLA-A2 and 50 mg melan-A ivt-RNA,
(3) 50 mg HLA-A2 and 25 mg melan-A ivt-RNA and (4) 50 mg HLA-A2 and 50 mg melan-A ivt-RNA. mDC of an HLA-A2
+ donor are transfected with (5) 25 mg
melan-A or (6) 50 mg melan-A ivt-RNA. Surface staining of HLA-A2 and intracellular staining of melan-A is performed 6 h after transfection and analyzed
by flow cytometry. HLA-A2 expression is represented by filled curves in the upper panels; the corresponding melan-A expression of the same sample is
shown beneath by filled curves. Corresponding controls are depicted in the respective histograms by open curves. (B) mDC of an HLA-A2
- donor are
electroporated with four different RNA combinations: (1) 25 mg HLA-A2 and 25 mg survivin ivt-RNA, (2) 25 mg HLA-A2 and 50 mg survivin ivt-RNA, (3) 50 mg
HLA-A2 and 25 mg survivin ivt-RNA and (4) 50 mg HLA-A2 and 50 mg survivin ivt-RNA. DC of an HLA-A2
+ donor are transfected with (5) 25 mg survivin or
(6) 50 mg survivin ivt-RNA. Surface staining of HLA-A2 is performed 6 h and intracellular staining of survivin 3 h after transfection and analyzed by flow
cytometry. HLA-A2 expression is represented by filled curves; corresponding survivin expression of the same sample is shown beneath by filled curves.
Corresponding controls are depicted in the respective histograms by open curves. (C) The percent positive cells, MFI and x-fold expression of all stainings
in (A and B) are shown.
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Figure4. For figure legend, see page 134.
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Induction of allo-restricted peptide-specific T cell lines using
ivt-RNA-pulsed mDC. The preceding studies established the
parameters for creating mDC that can be used as stimulating cells
for the induction of allo-restricted peptide-specific T cells using
CD8-enriched T cells that are prepared from the same donor as
the mDC. An experiment demonstrating the application of these
ivt-RNA-pulsed DC for T cell stimulation is shown in Figure5.
Here two comparisons are included: mDC were prepared from
HLA-A2
+ donors who carried an endogenous HLA-A*0201 allele
and thereby received only tyrosinase-encoding ivt-RNA while the
other mDC were prepared from HLA-A2
- donors that were
pulsed with ivt-RNA encoding both tyrosinase and HLA-A2.
These DC were used to directly prime enriched, autologous
CD8
+ T cells, using two rounds of in vitro stimulation with
freshly prepared mDC. Prior to activation and after the second
stimulation, the frequency of CD8
+ T cells bearing TCR specific
for HLA-A2-tyrosinase369–377-peptide ligand was measured using
anti-CD8 antibody and a tyrosinase369–377/HLA-A*0201-multimer.
Figure5. De novo priming of CD8
+ Tc e l l sw i t h
RNA-pulsed DC. mDC derived from an HLA-A2
+
donor transfected with 24 mgt y r o s i n a s ei v t -
RNA and mDC derived from an HLA-A2
- donor
transfected with 48 mgH L A - A 2a n d2 4mg
tyrosinase ivt-RNA are used for a de novo T cell
priming. (A) A2-tyr multimer staining (x-axis) of
CD8-enriched T cell populations are deter-
mined for cells obtained from an HLA-A2
+
donor and an HLA-A2
- donor before initiation
of primary cultures with ivt-RNA-loaded auto-
logous mDC and one day prior to cell sorting
(i.e., 6 d after the 2° stimulation). Staining for
CD8 is shown on the y-axis. The percentage of
multimer
+CD8
+ Tc e l l si sd i s p l a y e di nt h eu p p e r
right quadrant, showing an increase after mDC
stimulation. (B) Sorting scheme for two T cell
cultures derived from anHLA-A2
+(left diagram)
and an HLA-A2
- donor (right diagram). A2-tyr
multimer staining is shown on the x-axis and
CD8 staining on the y-axis. The boxed gates
represent the multimer
+CD8
+Tc e l lp o p u l a t i o n s
that are selected for fluorescence-activated cell
sorting. Dead cells are excluded by propidium
iodide staining (data not shown). MFI of
multimer staining is given for the gated cells in
the lower right corner and the percentage of
gated cells of total T cells is indicated beneath
the gates. (C) Before initiation of primary
cultures, CD8-enriched T cells are stained
simultaneously for A2-tyr multimer, CD8 and
either CD45RA or CD45RO. Histogram analysis
for CD45RA
+ and CD45RO
+ cells is performed
on gated multimer
+CD8
+ cells of both donors.
(D) Sorted T cells are expanded as bulk lines
and further re-analyzed after 7–22 d of culture
via A2-tyr multimer (x-axis) and CD8 (y-axis)
staining. T cell lines of two HLA-A2
+ and two
HLA-A2
- donors are depicted. Percentages of
multimer
+CD8
+ Tc e l l sa r ed i s p l a y e di nu p p e r
right quadrant and MFI for this population is
presented in lower right corner. T cells are
labeled for 45 min with themultimer and either
fixed immediately with 1% paraformaldehyde
(0 h) to determine MFI of multimer staining (i.e.,
Intensity) or 2 h after washing of cells to
remove unbound multimers with addition of
HLA-A2-specific antibody to prevent rebinding
of dissociated multimers to assess loss of
multimer binding (i.e., Off-rate). Specificity is
assessed with control HLA multimers, utilizing
peptides from the pp65 protein of cyto-
megalovirus bound either to HLA-B7 or HLA-A2
molecules (i.e., Specificity).
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Frequencies of multimer
+CD8
+ T cells were approximately equal
(0.46% and 0.49%) in enriched CD8
+ T cells before DC
stimulation (Fig.5A). Multimer
+CD8
+ cells that were detected
prior to DC stimulation revealed a phenotype of naïve T cells
since they were positive for CD45RA and negative for CD45RO
surface markers
19 (Fig.5C). The multimer
+ cell frequencies
increased to 0.65% of HLA-A2
+ and 1.39% of HLA-A2
- primed
T cells, based on total T cells at the end of the 2° co-culture
period (Fig.5A). One day later, cultures were harvested and
labeled with anti-CD8-antibody and A2-tyr multimer to perform
fluorescence-activated cell sorting. Multimer
+ cells were gated as
shown and isolated (Fig.5B). Distinct populations of multimer
+ T
cellsweremoredifficulttoidentifyinculturesfromHLA-A2
+donors
but were easy to delineate in cultures from HLA-A2
- donors. The
double-positive cells from the HLA-A2
+ donor shown here had a
relatively low mean fluorescence intensity (MFI) of multimer
binding (MFI = 3,963). In contrast, substantially higher multimer
staining intensity (MFI = 17,110) was seen on gated cells of the
HLA-A2
- donor. Sorted cells were cloned in limiting dilution
cultures and the remaining cells were expanded as bulk cultures
using antigen-independent stimulation.
19
Bulk cultures of multimer-sorted T cells were re-analyzed after
7–22 d of in vitro expansion. Results are presented from four
different donors, primed and sorted according to the full experi-
mental procedure depicted in Figure1. As expected, the majority
of cells were CD8
+ in all four T cell lines (Fig.5D). MFI of
multimer binding was used as a first estimate of structural TCR-
pMHC binding affinity since higher multimer staining intensity
has been shown to indicate a stronger interaction of TCR with
their ligands.
20 Multimer
+ cells were present in the cultures of
HLA-A2
+ donors at frequencies of 11.2% and 8.3%, respectively.
These T cells had low-intermediate intensities of multimer
binding (MFI = 414 and 227). Apparently, substantial numbers
of non-specific T cells were gated and sorted. In contrast, 93.1%
and 78.2% of sorted cells of the two HLA-A2
- donors bound
HLA-multimers with higher intensities (MFI = 1,176 and 1,433).
We also measured loss of HLA-multimer binding over time (i.e.
HLA-multimer off-rate) as a second parameter of structural TCR-
pMHC binding affinity. A slower off-rate indicates that the TCR-
ligand interactions are more stable and thereby of higher structural
affinity.
21 After initial incubation with HLA-multimer and
washing, the T cells were incubated for 2 h at 4°C in the absence
of multimer and the presence of antibody specific for HLA-A2
molecules to prevent cellular re-association of released multimers.
The rapid loss of multimer binding in T cells of HLA-A2
+ donors
indicated that the self-MHC-restricted T cells were of lower TCR
affinity. After 2 h only 6.2% and 1.7% of the T cells were
multimer
+, accounting for losses of 45% and 79%, respectively.
Multimer binding of T cells from HLA-A2
- donors was more
stable over time, indicating a higher structural TCR binding
affinity for the same pMHC ligands. After 2 h, 68.3% and 60.3%
of the cells were multimer
+, accounting for losses of only 27% and
23%, respectively. Specificity of multimer binding was confirmed
using two control multimers, containing peptides derived from
cytomegalovirus protein pp65. Both the HLA-B7-pp65 and
HLA-A2-pp65 multimers showed negligible binding to the four
T cell lines (0.1–1.0%). These results revealed that bulk T cell
cultures containing highly enriched numbers of multimer
+ T cells
could be readily generated using the detailed experimental pro-
cedure. After expansion, the T cell lines can be further enriched
by multimer sorting or they can serve as a source of T cell clones
that can be isolated by single cell sorting or limiting dilution
cultures. We have found that it is equally feasible to establish
limiting dilution cultures directly from the multimer-sorted T
cells on day 14 of the experimental procedure.
22
Extensive analysis of tyrosinase-specific T cell clones derived
from both types of priming cultures have been published
elsewhere. These studies demonstrated that substantial numbers
of allo-restricted tyrosinase-peptide specific T cell clones could be
established by this procedure. They represented about 30% of the
clones isolated from the HLA-A2
- donors. They were able to
secrete IFNc and mediated strong killing of peptide-pulsed
antigen-presenting cells, but most importantly, they also secreted
high levels of cytokine and showed strong specific killing of
HLA-A2
+ melanoma tumor cells that also expressed tyrosinase. T
cell clones were also isolated from the HLA-A2
+ donors but they
showed lower levels of cytokine secretion and tumor cell killing.
23
Discussion
The experimental procedure described here provides a highly
flexible method to generate allo-restricted peptide-specific T cell
lines and clones. We have applied this experimental approach to
generate HLA-A2-allo-restricted T cell clones specific for tyrosi-
nase, survivin,
22 melan-A (unpublished observations), hyaluronan-
mediated motility receptor (HMMR), Wilm’s tumor -1 (WT-1),
NY-ESO among others. Two specificities of T cells arise in the
priming cultures using mDC expressing new allogeneic MHC
molecules and TAA. Since the responding cells and DC are derived
from HLA-A2
- donors, one fraction of T cell clones recognizes the
transgenic HLA-A2 as an alloantigen, irrespective of specific TAA-
derived peptide. The second fraction recognizes a TAA-derived
peptide in association with allogeneic HLA-A2 molecules. These
two types of response must be separated at the level of individual
clones. We observed that about 50% of the multimer-sorted cells
arising in the allogeneic co-cultures recognized HLA-A2 as an
alloantigen, independent of TAA-derived peptide. Fortunately,
after multimer sorting and cloning at the end of the 2° co-culture
period around 30% of the T cell clones were allo-restricted and
peptide-specific.Asexpected,none oftheTcellclonesderived from
HLA-A2
+ donors showed HLA-A2 alloreactivity. Thus, this
experimental procedure provides a robust method for efficiently
obtaining a variety of different T cell clones for further study.
The preparation of mDC as stimulating cells is a particularly
critical component of the experimental procedure. The use of
different combinations of ivt-RNA encoding MHC and TAA
showed that the method is reliable for obtaining good co-
expression of both proteins. In essence it can be used for any
MHC allele and TAA for which cDNA are available to generate
ivt-RNA. However it is important to track the expression of both
the MHC and the TAA in mDC to assure adequate co-expression
of the proteins. In the first instance, this can be done using flow
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cytometry to detect expression of the new proteins. Ideally,
detection of a new pMHC ligand through recognition of a specific
T cell clone is useful to demonstrate that the functions of antigen
processing and presentation are intact in the mDC. This may not
always be feasible due to lack of specific T cell clones.
Because the entire TAA appears as an intracellular protein, it
can be processed and presented by the natural antigen processing
machinery of the mDC, thereby creating multiple new epitopes at
the cell surface, often of unknown sequence. For known pMHC
ligands, specific T cells can be sorted using multimers. For T cells
of unknown peptide specificity, other isolation procedures can
be employed, such as cytokine capture or CD137 expression
(unpublished observations) after APC stimulation.
24 Thereby, this
method opens the possibility to tap T cells with high functional
avidities for many new TAA specificities.
The major advantage of this experimental procedure is that
responding CD8
+ T cells and mDC can be used from any healthy
donor who does not carry the HLA-allotype that is selected as
the molecule for allo-restriction. This eliminates the need for
extensive searches of HLA-typed donors to identify partial HLA-
mismatched pairs that differ by only one HLA-allotype. Because
an extensive bank of cDNA for different HLA alleles is available,
or they can be quickly isolated from any donor of choice, studies
of TAA presentation by HLA molecules other than HLA-A2 are
now much easier to perform. Furthermore, it is possible to extend
the studies to TAA presentation by MHC class II molecules using
the same experimental procedure, with the modification that the
TAA-encoding ivt-RNA should be modified to target the protein
to the class II presentation pathway.
25
Materials and Methods
Culture of cell lines and effector T cell clones. The human
melanoma cell line Mel-93.04A12 (HLA-A2
+ tyrosinase
+ melan-
A
+; gift of P. Schrier, Department of Immunohematology, Leiden
University Hospital, The Netherlands) is cultured in RPMI 1640
medium (Invitrogen, 318725) supplemented with 12% fetal
bovine serum (FBS) (Invitrogen, 10091148), 2 mM L-glutamine
(Invitrogen, 25030-024) and 1 mM sodium-pyruvate (Invitrogen,
11360039) and non-essential amino acids (Invitrogen, 11140035).
For pre-testing the stimulatory capacitiy of ivt-RNA-pulsed
mDC, the HLA-A2 allo-specific CTL JB4
17 and the HLA-
A*0201-restricted tyrosinase369–377 peptide-specific CTL Tyr-
F8
18 (gift of P. Schrier, Department of Clinical Oncology, Leiden
University Hospital, The Netherlands) are cultured as described.
Generation of DC. Blood samples from healthy donors are
collected after informed consent, in accordance with the Declara-
tion of Helsinki and approval of the Institutional Review Board of
the University Hospital of the Ludwig-Maximilians-University,
Munich, Germany. Peripheral blood mononuclear cells (PBMC)
are isolated by Ficoll density gradient centrifugation. PBMC are
resuspended in 15 ml VLE (very low endotoxin) RPMI 1640
medium (Biochrom, FG1415) supplemented with 1.5% human
serum (DC medium) at 7.5'10
7 cells per 75 cm
2 culture flask
(NUNC, 178905) and incubated at 37°C and 5% CO2 for 1 h.
Non-adherent cells are carefully removed by washing. Adherent
monocytes are cultured in medium containing 100 ng/ml GM-
CSF (Leukine
1 by Berlex, NDC50419-050-30) and 20 ng/ml
interleukin-4 (R&D Systems, 104-IL-050-CF) and fed with the
same medium on days 3 and 6. On day 6 of culture, the immature
DC are differentiated into mDC by addition of medium
containing 10 ng/ml IL-1  (R&D Systems, 201-LB-025-CF),
15 ng/ml IL-6 (R&D Systems, 206-IL-050-CF), 10 ng/ml TNFa
(R&D Systems, 210-TA-050-CF) and 1 mg/ml PGE2 (Sigma-
Aldrich, p5640-10MG) for 2 d.
Production of HLA-A2, tyrosinase, melan-A and survivin ivt-
RNA. The following linearized plasmids were used as in vitro
transcription templates to produce single-species ivt-RNA with
the aid of the mMESSAGE mMACHINE T7 kit and Poly(A)
tailing kit (both Ambion, AM1344 and AM1350), according to
the manufacturer’s instructions: pCDM8-HLA-A2 plasmid with
HLA-A*0201 cDNA (gift of E. Weiß, Department Biology II,
Ludwig-Maximilian-University, Munich, Germany), pZeoSV2+/
huTyr with tyrosinase cDNA (gift of I. Drexler, Institute of
Molecular Virology, Helmholtz Zentrum München, Munich,
Germany), pcDNAI/Amp/Aa1 with melan-A cDNA (gift of T.
Wölfel,ThirdDepartmentofMedicine,Hematologyand Oncology,
Johannes-Gutenberg University of Mainz, Mainz, Germany) and
pGEM4Z/survivin/A64 plasmid (cloned byS. Milosevic, Institute of
Molecular Immunology, Helmholtz Zentrum München).
Also different modified mRNA molecules (RNActive
1,
CureVac) were used that encode HLA-A2 molecules. Four
different HLA-A2 mRNA are compared, here whereby the 3'
untranslated region of either the human a-globin or  -globin gene
is linked to the HLA-A2 construct in different ways, leading to
a-globin or  -globin stabilized HLA-A2 mRNA.
Electroporation of DC. On day 8, mDC are harvested 48 h
after addition of maturation cytokines. Electroporation is per-
formed as previously described.
16 In brief, 2 to 3x10
6 cells are
resuspended in approximately 200–300 ml OptiMEM I medium
(Invitrogen, 31985047), placed in a 0.4-cm electroporation
cuvette (Bio-Rad, 5000835) and incubated for 3 min on ice.
Electroporation is performed with the Gene Pulser Xcell (Bio-
Rad) using the exponential protocol at 250 V and 150 mF. RNA
species are transfected using different amounts of individual
RNA, between 24–50 mg per electroporation.
FACS analysis. HLA-A2 molecules are stained on the surface
of DC with BB7.2 monoclonal antibody (HB82, ATCC) for
45 min on ice followed by a secondary antibody conjugated with
phycoerythrin (PE) (goat anti-mouse IgG; Jackson Immuno-
Research, 115-116-146) for 45 min. The intracellular protein
expression in ivt-RNA-transfected mDC is detected using the
following primary antibodies: tyrosinase-specific primary mono-
clonal antibody (clone T311; diluted 1:10; Novocastra Labo-
ratories Ltd., 600741), melan-A-specific primary monoclonal
antibody (clone A103; diluted 1:20; DakoCytomation, M7196)
and survivin-specific primary monoclonal antibody (clone 91630;
diluted 1:2.5; R&D Systems, MAB886) followed by staining
with Cy5-conjugated secondary antibody (rat anti-mouse IgG;
Jackson ImmunoResearch, 415-176-166). The intracellular
staining is performed as follows. The mDC samples are first
fixed in FACS buffer containing 1% paraformaldehyde (Sigma,
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P6148-1KG) for 30 min on ice and washed twice in buffer
without additives and once in buffer containing 0.1% saponin
(Sigma, S4521-25G). Samples are then incubated with primary
antibody in buffer containing 0.25% saponin for 1 h at room
temperature, washed once in buffer containing 0.1% saponin and
stained for 30 min at room temperature in the dark with the Cy5-
conjugated secondary antibody, diluted in buffer containing
0.25% saponin. Cells are washed once and resuspended in buffer
with 0.1% saponin. Untransfected mDC are treated in the same
manner and used as negative controls. Data acquisition and ana-
lysis are done on a FACSCalibur (BD Biosciences) using CellQuest
Pro software or FloJo software (Tree Star). X-fold expression is
calculatedbydividing the mean fluorescence of ivt-RNA-transfected
mDC by the mean fluorescence of untransfected mDC.
To determine the phenotype of unprimed multimer
+CD8
+ T
cells, cells are double-stained with PE-labeled HLA-A2 tyrosi-
nase369–377 (YMDGTMSQV) (A2-tyr) multimer,
26 CD8-specific
antibody (clone RPA-T8, BD PharMingen, 555369) and simul-
taneously with either CD45RO- (clone UCHL1, Immunotech,
IM1247) or CD45RA-specific (clone HI100, BD PharMingen,
550855) antibody. Histogram analysis for CD45RO and
CD45RA staining is performed on gated multimer
+CD8
+ T cells.
Data acquisition and analysis are made with an LSRII instrument
(BD Biosciences) using FloJo software (Tree Star).
IFNc release assay. Stimulatory capacity of RNA-pulsed mDC
is analyzed 24 h after electroporation. JB4 or Tyr-F8 CTL
suspensions (2   10
4 cells in 100 ml) are added to the RNA-
loaded mDC (4   10
4 cells in 100 ml) in round-bottom 96-well
plates. T cells without stimulator cells and with mock-transfected
mDC serve as negative controls and show almost no IFNc
secretion. T cells are co-cultured with the HLA-A2
+, tyrosinase
+,
melan-A
+ tumor cell line Mel-93.04A12, as positive control.
Culture supernatants are harvested after 24 h co-culture and
assessed by a standard ELISA using the OptEIA
TM Human IFNc
Set (BD Biosciences, 555142). Data represent mean values
with corresponding mean deviations calculated from duplicate
determinations.
De novo priming of T cells with ivt-RNA-pulsed DC. mDC
are transfected with pre-selected optimal ivt-RNA concentrations
via electroporation as described above. mDC derived from HLA-
A2
+ donors are loaded with 24 mg tyrosinase ivt-RNA and mDC
prepared from HLA-A2
- donors are co-transfected with 24 mg
tyrosinase and 48 mg HLA-A2 ivt-RNA. Untouched autologous
CD8
+ T lymphocytes are enriched from PBMC via negative
selection using a commercial kit, according to the manufacturer’s
instructions (CD8
+ T Cell Isolation Kit, Miltenyi Biotec, 130-
094-156) on the same day. Co-cultures are initiated 10 h after
electroporation in 24-well plates (TPP, Z707805-64EA). 1   10
5
ivt-RNA-pulsed mDC are added to 1   10
6 CD8
+ T cells,
yielding a mDC:T cell ratio of 1:10 in T cell medium consisting
of RPMI 1640 (Invitrogen, 318725), supplemented with 10%
heat inactivated human serum, 4 mM L-glutamine (Invitrogen,
25030-024), 12.5 mM HEPES (Invitrogen, -15630049),5 0mM
 -mercaptoethanol (Sigma, -63700-50ML-F) and 100 U/ml
penicillin/streptomycin (Invitrogen, -15070063). On day 0, 5 ng/ml
IL-7 (Promokine, -C-61712) is added. Addition of IL-2
(Proleukin
1S, Novartis) is delayed for 2 d to decrease proliferation
of non-specific CD8
+ Tc e l l s ,
19 then it is added every 3rd day. The
2nd stimulation of the primed T cells is made seven days later using
freshly generated ivt-RNA-pulsed mDC, prepared as above.
HLA-multimer staining and sorting. Prior to priming and six
days after the 2nd stimulation of CD8-enriched T cells with
ivt-RNA-pulsed mDC, HLA-A2-restricted tyrosinase-specific T
cells are detected by staining with PE-labeled HLA-A2 tyrosi-
nase369–377 (YMDGTMSQV) (A2-tyr) multimer,
26 CD8-specific
antibody (clone RPA-T8, BD PharMingen) and propidium iodide
(PI: 2 mg/ml). Up to 1   10
6 cells are incubated in 50 ml volume
for 25 min with 4 mg PE-labeled multimer on ice in the dark. For
sorting, multiple samples of up to 5   10
6 cells are incubated with
12 mg multimer in 100 ml PBS + 0.5% human serum. APC-
labeled, CD8-specific antibody is then added for an additional
25 min. After staining, an aliquot of cells is washed and fixed for
analysis by flow cytometry using a FACSCalibur (BD Biosciences)
and the remaining cells are pooled and sorted on a FACS Aria
instrument (BD Biosciences) as described.
27
Toobserve HLA-multimer dissociation (off-rate),cells arewashed
after multimer binding and resuspended in FACS buffer containing
saturatingamountsofmonoclonalHLA-A2-specificBB7.2antibody
to capture detached multimers and prevent rebinding to T cells.
After 2 h, samples are fixed and analyzed by flow cytometry.
21 PE-
labeled HLA-B7/pp65417–427 (TPRVTGGGAM) peptide/human
 2m multimers serve as the HLA control and HLA-A*0201/
pp65495–503 (NLVPMVATV) peptide/human  2m multimers serve
as a peptide-specificity control. Peptides for these multimers are
derived from the pp65 protein of human cytomegalovirus.
Culture of peptide-specific T cell lines. Multimer-sorted T
cells are expanded as bulk T cell lines in 96-well round-bottom
plates (TPP, 5000773) in 200 ml/well T cell medium (600 cells
per well). 50 IU/ml IL-2 is supplemented every three days with
5 ng/ml IL-7 (Promokine, C-61712) and 10 ng/ml IL-15
(PeproTech Inc., AF-200-15) every seven days. Every 14 d T cell
lines are restimulated non-specifically with anti-CD3 antibody
(0.1 mg/ml) (OKT-3; gift of E. Kremmer, Institute of Molecular
Immunology, Helmholtz Zentrum München) and provided with
1   10
5 feeder cells per 96-well (TPP, 92097), consisting of
irradiated (50 Gy) PBMC derived from a pool of five unrelated
donors. Proliferating T cells are transferred into 24-well plates
(TPP, Z707805-64EA) and cultured in 1.5 ml T cell medium
plus cytokines. 1   10
6 allogeneic irradiated PBMC are added per
well as feeder cells in 24-well plates.
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